LENZ Therapeutics Files 8-K
Ticker: LENZ · Form: 8-K · Filed: Oct 8, 2025 · CIK: 1815776
| Field | Detail |
|---|---|
| Company | Lenz Therapeutics, Inc. (LENZ) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001, $45.75, $80,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing
TL;DR
LENZ Therapeutics filed an 8-K for an 'Other Event' on Oct 8, 2025. Details pending.
AI Summary
LENZ Therapeutics, Inc. filed an 8-K on October 8, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it confirms the company's reporting status and provides its corporate information. LENZ Therapeutics, formerly known as Graphite Bio, Inc. and Integral Medicines, Inc., is incorporated in Delaware and headquartered in Solana Beach, California.
Why It Matters
This filing indicates a material event has occurred for LENZ Therapeutics, requiring public disclosure. Investors should monitor for further information to understand the nature and impact of this event.
Risk Assessment
Risk Level: medium — An 8-K filing signals a significant event, but the lack of detail in this specific filing creates uncertainty about the associated risks.
Key Numbers
- 001-40532 — SEC File Number (Identifies the company's filing history with the SEC.)
- 84-4867570 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- LENZ Therapeutics, Inc. (company) — Registrant
- October 8, 2025 (date) — Date of earliest event reported
- Graphite Bio, Inc. (company) — Former company name
- Integral Medicines, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Solana Beach, California (location) — Principal executive offices
FAQ
What specific event is being reported in this 8-K filing?
The filing states 'Other Events' as the item information, but does not provide specific details about the nature of the event.
When was the earliest event reported in this filing?
The earliest event reported was on October 8, 2025.
What were the previous names of LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. was formerly known as Graphite Bio, Inc. and Integral Medicines, Inc.
In which state is LENZ Therapeutics, Inc. incorporated?
LENZ Therapeutics, Inc. is incorporated in Delaware.
What is the address of LENZ Therapeutics, Inc.'s principal executive offices?
The principal executive offices are located at 201 Lomas Santa Fe Dr., Suite 300, Solana Beach, California 92075.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-10-08 16:40:46
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share LENZ The Nasdaq Stock Market
- $45.75 — of common stock at a purchase price of $45.75 per share for gross proceeds of approxi
- $80,000,000 — are for gross proceeds of approximately $80,000,000 in a block trade to a single investor u
Filing Documents
- lenz-20251008.htm (8-K) — 23KB
- 0001815776-25-000064.txt ( ) — 141KB
- lenz-20251008.xsd (EX-101.SCH) — 2KB
- lenz-20251008_lab.xml (EX-101.LAB) — 23KB
- lenz-20251008_pre.xml (EX-101.PRE) — 13KB
- lenz-20251008_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 7, 2025, the Company sold 1,748,634 shares of common stock at a purchase price of $45.75 per share for gross proceeds of approximately $80,000,000 in a block trade to a single investor under the Company's "at the market" Sales Agreement with TD Securities (USA) LLC, dated as of April 4, 2025 (the "Sales Agreement"). The sale was made pursuant and subject to the terms of the Sales Agreement, a copy of which was filed with the Current Report on Form 8-K filed by the Company on April 4, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 8, 2025 LENZ THERAPEUTICS, INC. By: /s/ Daniel Chevallard Name: Daniel Chevallard Title: Chief Financial Officer (Principal Financial and Accounting Officer)